IL18 and cancer: These antibodies also mediate a beneficial proinflammatory response in cancer through enhanced induction of IFN-γ and other cytokines, and in combination with the PD-1 antibody they potentiate the activity of IL-18 immunotherapy by inhibiting the checkpoint activity of IL-18BP and enhancing the immune response of NK cells and T cells (Jun et al., 2023 [141]).